Dynamics of blast percentage and mutational burdens throughout the course of therapy. Blast percentages observed by BM morphologic evaluation are represented over time as blue shaded areas, with blast populations defined by flow cytometry represented as dotted gray lines. VAFs of somatic mutations are depicted over time in each patient. Clearance of NPM1 mutations can be observed in patients who respond to therapy (UPN 4, UPN 5, UPN 18, UPN 22, UPN 23, UPN 27, UPN 28, UPN 30, and UPN 31) or after allogeneic stem cell transplantation (UPN 19 and UPN 21). Disease relapses or progression were invariably associated with resurgence of NPM1 mutations, with correlation between mutation burden and blast population (UPN 4, UPN 7, UPN 22, UPN 24, UPN 25, UPN 28, and UPN 30). Acquisition of new clonal abnormalities was associated with transformation or relapse in a number of patients (UPN 4, UPN 7, UPN 22, UPN 24, UPN 25, UPN 28, and UPN 30). CLIA, cladribine, idarubicin, cytarabine.